Changes in Hong Kong stocks | Luye Pharmaceutical (02186) rose more than 6% in early trading, the mRNA vaccine LY01620 is about to launch phase II clinical trials in China

The Zhitong Finance App learned that Luye Pharmaceutical (02186) rose more than 6% in early trading. As of press release, it had risen 6.53% to HK$2.28, with a turnover of HK$42.4818 million.

According to the news, on August 20, Luye Pharmaceutical announced that the messenger ribonucleic acid (mRNA) vaccine LY01620, developed independently by the group, will soon conduct phase II clinical trials in China. The study is intended to include histologically confirmed human papillomavirus16 (HPV16) -positive high-grade cervical squamous intraepithelial lesion (HSIL) patients to further evaluate the efficacy and safety of LY01620.

Compared with traditional surgical treatment, therapeutic vaccines can be applied to different stages of the disease after HPV infection to block progression to cervical cancer. Group management believes that the development of a therapeutic HPV vaccine has become an urgent clinical requirement as an efficient non-surgical immunotherapy program. LY01620 is expected to fill the gap in HPV therapeutic vaccines and provide new treatment options for HPV-related diseases. In addition, the Group is also actively exploring the clinical application prospects of LY01620 in HPV-related solid tumors to further explore the therapeutic value and potential of potential products.